Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for Neuroinflammation.

Journal of medicinal chemistry·2026
Same author

Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting.

Circulation·2026
Same author

Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model.

Bioorganic & medicinal chemistry letters·2022
Same author

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

Journal of medicinal chemistry·2021
Same author

Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.

Bioorganic & medicinal chemistry·2021
Same author

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.

Journal of medicinal chemistry·2020
Same journal

Green, renewable, or low-carbon? A framework for informed solvent selection in pharmaceutical sciences.

Journal of pharmaceutical sciences·2026
Same journal

Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI.

Journal of pharmaceutical sciences·2026
Same journal

Intranasal mucoadhesive chitosan microspheres of ranolazine: Formulation, design, and pharmacokinetic evaluation.

Journal of pharmaceutical sciences·2026
Same journal

Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Journal of pharmaceutical sciences·2026
Same journal

A mathematical framework for predicting tablet weight variability from blend particle size distribution and tooling geometry.

Journal of pharmaceutical sciences·2026
Same journal

Recrystallization can stop nitrosamine formation in ranitidine hydrochloride.

Journal of pharmaceutical sciences·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins
10:05

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins

Published on: August 7, 2014

Plasma protein binding: from discovery to development.

Tonika Bohnert1, Liang-Shang Gan

  • 1Preclinical PK & In Vitro ADME, Biogen Idec Inc., Cambridge, Massachusetts 02142, USA. tonika.bohnert@biogenidec.com

Journal of Pharmaceutical Sciences
|June 27, 2013
PubMed
Summary
This summary is machine-generated.

Plasma protein binding (PPB) influences drug effectiveness and potential toxicity. Understanding unbound drug concentrations is crucial for accurate dosing, predicting drug interactions, and ensuring safety during drug development.

Keywords:
albuminalpha 1-acid glycoproteinblood-brain barrierdrug interactionsprotein binding

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Experiment Videos

Last Updated: May 10, 2026

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins
10:05

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins

Published on: August 7, 2014

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Area of Science:

  • Pharmacology
  • Drug Development
  • Biochemistry

Background:

  • Plasma protein binding (PPB) significantly impacts the free drug concentration available at target sites.
  • Free drug theory posits that unbound drug levels in plasma equilibrate with those at pharmacologic receptors.
  • Changes in free drug concentration can indicate potential toxicity and necessitate dose adjustments.

Purpose of the Study:

  • To review the role of PPB across various therapeutic areas.
  • To highlight clinically significant alterations in PPB.
  • To offer recommendations for drug metabolism and pharmacokinetics (DMPK) in drug discovery and development.

Main Methods:

  • Literature review of studies reporting PPB.
  • Analysis of cases with clinically relevant PPB changes.
  • Synthesis of DMPK recommendations based on PPB data.

Main Results:

  • PPB is a critical factor in pharmacokinetics/pharmacodynamics (PK/PD) relationships.
  • Unbound drug concentration is key for predicting drug-drug interactions.
  • Cross-species PPB data aids in establishing safety margins and selecting appropriate doses for human trials.

Conclusions:

  • Accurate assessment of PPB is vital for successful drug development.
  • Understanding PPB variability informs safety and efficacy predictions.
  • Integrating PPB insights into early drug development optimizes compound progression.